US · Healthcare · Biotechnology
EPS came in at -0.49 against a street estimate of -0.45 — a miss of 8.9%.
Analysts rate Contineum Therapeutics, Inc. Class A Common Stock a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $22.14.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 7.55% |
| Jupiter Topco LLC | 7.27% |
| BlackRock Inc | 5.49% |
| Johnson & Johnson | 5.26% |
| Franklin Templeton Inc | 4.89% |
| Balyasny Asset Management LLC | 4.05% |
| Vanguard Capital Management, LLC | 3.51% |
| Perceptive Advisors LLC | 3.34% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Contineum Therapeutics, Inc. Class A Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.